CEFOTIAM HEXETIL IN RESPIRATORY TRACT INFECTION

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement6; pp. 251 - 255
• Main Authors: HAYASHI, IZUMI, OHNUMA, KIKUO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• Subjects: Cefotiam hexetil
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement6_251

We perfomed a clinical evaluation of cefotiam hexetil (CTM-HE) in 7 patients with respiratory tract infection. These consisted of 5 males and 2 females aged from 34 to 80 years. Cefotiam hexetil was given orally in daily doses of 600 mg in three divided portions. The duration of administration was 7 days in 5 cases, and 10 and 14 days in one case each. A total of 4 strains, comprising 2 of Streptococcus pneumoniae, 1 of Staphylococcus aureus and 1 of Acinetobacter calcoaceticus, were identified from the sputum before administration. S. pneumoniae and S. aureus were eradicated but A. calcoaceticus remained, while one strain of S. aureus appered after the treatment. The clinical efficacy rate was 100%: excellent in 2 cases and good in 5. There were no side effects, but slight elevation of GPT was observed in one case. From the above results, we conclude that cefotiam hexetil is an effective, safe and useful new oral cephem.